GlassScriptPhysician profile
Jeffrey Sparks
NPI 1356546063
$299,145.04
in general payments reported to CMS, 2019-2025
25 companies · $60K in 2025
The $60K reported for 2025 was more than what 97% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $16K · 2021: $35K · 2022: $44K · 2023: $75K · 2024: $38K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $100K · Travel and Lodging: $39K · Honoraria: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $5,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $99,636.23 |
| Travel and Lodging | $38,956.52 |
| Honoraria | $14,813.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,691.40 |
| Food and Beverage | $5,464.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $51,539.27 | 2019-2025 | |
| Boehringer Ingelheim International Gmbh | $45,785.65 | 2021-2025 | Ofev |
| Abbvie INC. | $36,894.66 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $35,270.48 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,735.52 | 2021-2025 | Ofev |
| Novartis Pharmaceuticals Corporation | $20,268.67 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $16,657.27 | 2022-2025 | Tremfya |
| Janssen Biotech, INC. | $9,766.90 | 2022 | |
| Merck Sharp & Dohme LLC | $9,617.01 | 2019-2025 | |
| Gilead Sciences, INC. | $9,097.65 | 2019 | |
| Ucb, INC. | $7,640.65 | 2023-2025 | Bimzelx, Cimzia |
| Fresenius Kabi USA, LLC | $5,100.00 | 2023 | |
| Sun Pharmaceutical Industries INC. | $5,022.93 | 2025 | |
| Janssen Global Services, LLC | $4,320.00 | 2021 | |
| Inova Diagnostics, INC. | $3,750.00 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,500.00 | 2022 | |
| Sobi, INC | $2,160.00 | 2023 | |
| Invivyd INC | $2,012.50 | 2025 | Pemgarda |
| Ani Pharmaceuticals, INC. | $1,950.00 | 2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $1,902.62 | 2019 | |
| Genzyme Corporation | $1,902.27 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,636.85 | 2024-2025 | Saphnelo |
| Genentech, INC. | $737.88 | 2025 | |
| Genentech USA, INC. | $722.74 | 2019 | |
| Assertio Therapeutics, INC. | $153.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Sparks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.